Thursday April 12, 2018

**Session 1: Advances in Myelodysplasia**
Moderators: Hetty Carraway, MD  
B. Douglas Smith, MD

1:00  Introduction  
*Jacob M. Rowe, MD, Co-Chairman*

1:05-1:20  What biologic factors predict for transformation to AML?  
*Rafael Bejar, MD, PhD*

1:20-1:30  Discussion

1:30-1:45  Do molecular genetics drive therapeutic strategy in MDS?  
*Stephen Nimer, MD*

1:45-1:55  Discussion

1:55-2:10  Must hypomethylating agents be given prior to transplant?  
*Mikkael Sekeres, MD, MS*

2:10-2:20  Discussion

2:20-2:35  What is the optimal strategy for patients with who have failed hypomethylating therapy?  
*Rami Komrokji, MD*

2:35-2:45  Discussion

2:45-3:05  Break

**Session 2: Novel Strategies in ALL**
Moderators: Dan Douer, MD  
Richard Larson, MD

3:05-3:20  Why and how to treat Ph-like ALL?  
*Kathryn G. Roberts, PhD*

3:20-3:30  Discussion

3:30-3:45  Is transplant still an imperative in Ph+ ALL?  
*Mark Litzow, MD*

3:45-3:55  Discussion
3:55-4:10  Can one target T-cell ALL?  
*Adolfo Ferrando, MD, PhD*

4:10-4:20  Discussion

4:20-4:35  Should immunologic strategies be incorporated into newly diagnosed ALL?  
*Wendy Stock, MD*

4:35-4:45  Discussion

4:45-5:30  Oral poster presenters (3)  
Each 10 minutes; 5 minutes Q & A

5:30-6:15  Poster Session/Reception

6:30-9:00  CME Dinner Symposium  
*The changing landscape for acute myeloid leukemia*

**Friday April 13, 2018**

7:00–7:40  Registration and Breakfast

7:45–7:50  Introduction  
*Jacob M. Rowe, MD, Co-Chairman*

**Session 1: Basic Biology**
Moderators:  
*Ross Levine, MD*  
*Marshall Lichtman, MD*

7:50–8:05  Mutational complexity in AML  
*Omar Abdel-Wahab, MD*

8:05–8:15  Discussion

8:15–8:30  Genetic predisposition to AML  
*Lucy Godley, MD*

8:30–8:40  Discussion

8:40–8:55  Mechanisms of resistance in TP53 mutated AML  
*John S. Welch, MD, PhD*

8:55–9:05  Discussion

9:05–9:25  Break
Session 2: Therapy of Induction, Post-remission and Relapse

Moderators: Harry Erba, MD, PhD
Selina Luger, MD

9:30–9:45 Is there a standard of care for relapsed AML?
Bruno Medeiros, MD

9:45–9:55 Discussion

9:55–10:10 Is the overall survival for older adults finally improving?
Jeffrey E. Lancet, MD

10:10–10:20 Discussion

10:20–10:35 Which novel agents are likely to change practice?
Daniel Pollyea, MD

10:35–10:45 Discussion

10:45–11:00 Is it time to routinely incorporate MRD into practice?
Farhad Ravandi, MD

11:00–11:10 Discussion

11:10–11:25 Which FLT3 inhibitor holds the greatest promise?
Richard M. Stone, MD

11:25–11:35 Discussion

11:35–12:35 Lunch

Session 3: Bone Marrow Transplantation

Moderators: Armand Keating, MD
Stephanie Lee, MD

12:40–12:55 Who should be transplanted at diagnosis, without any pre-transplant therapy?
Robert J. Soiffer, MD

12:55–1:05 Discussion

1:05–1:20 When to transplant an AML patient who is MRD-positive post-consolidation?
Frederick R. Appelbaum, MD

1:20–1:30 Discussion
Are haploidentical transplants now the preferred alternative donor graft source?  
Daniel J. Weisdorf, MD

Why is a 3-year NRM following allogeneic transplantation still stuck at approximately 20%?  
John Barrett, MD

Session 4: Supportive Care and Perspective
Moderators: Nancy Berliner, MD  
            Kenneth Kaushansky, MD

Immune reconstruction following ablative and non-myeloablative therapies  
Marcel RM van den Brink, MD, PhD

Ernest Beutler Memorial Lecture
Introduction  
Aaron Rapoport, MD

CAR-T Therapy. From Bench to the Bedside  
Carl June, MD

Concluding Remarks and Close  
Martin S. Tallman, MD, Co-Chairman